I've revised my estimates. The biotech index has been slammed in Q1 and has been a lagging indicator. Looks like that is changing and is catching up with the rest of the indexes. If it continues, and there is no huge downturn in the markets, NKTR could easily hit 20 pps by June.
With no news expected till second half of the year, this stock will essentially move with the biotech index. The biotech index has been crushed lately and looks to recover along with the rest of the market. When that happens, I see this potentially hitting 4 -5 pps along with expected news second half.
Nektar outpacing sector on very good strength. We should see 16 in no time leading up to earnings early June. I picked my purchase perfectly at 10.80. I'll start off loading some at 16-17 on the next short squeeze.
Valeant Pharmaceuticals. Took the entire sector down this week. Valeant is the next Enron. NKTR follows the NBI index. I'm hoping the index starts to recover and catch up with the rest of the indices after being slammed this year.
GERN plunged around 10% about the same time as the Valieant announcement that brought the entire sector down. Most biotech stocks like Gern follow the Nasdaq biotechnology index NBI that also fell by almost the same. I hope when the dust settles GERN will recover and continue a run up along with NBI that has been battered this year.
Valeant Pharmaceuticals. It has the entire sector down the last two days. It will become the next Enron soon and will implode further IMHO that will unfortunately place more pressure on biotech stocks
What I'm waiting for is a shot squeeze. The biotech sector has not recovered during this huge run up in the market. It will eventually catch up forcing the shorts to cover. This will lead to NKTR price appreciating significantly. I don't understand the logic of shorting at this point. I think the PPS is like a coiled spring waiting to pop.
I agree, this stock is a trade not an investment. Just picked up some at around the same price after selling my prior shares at average price of 15.5
Nasdaq has been way overvalued. It may be 2000 deja vu all over again. When you get companies like LinkedIn dropping 45% for an earnings miss and the big boys FB, AMZN etc getting punished, the current economic cycle for tech stocks is ending and correction is now beginning to find justified valuations. I predict we'll see a leg lower in the next 1- 2 years when it hits rock bottom.
If the bubble continues, NKTR will obviously be swept in with other tech stocks so there's no telling what the true valuation will be. 4-5 bucks is not inconceivable based on history. Thought tempting to buy at these levels, I'm hesitant.
From 11 to 17 bucks pps now cycling back down to 11. I bought at around 11 then sold on the way up to 17 with an average pps of around 15. I'll start another position at 11. For the past 20 years, NKTR has never been an investment. It's been a trade.
Looks like the pending NKTR 214 first patient dose announcement and Adnovate approval in December are beginning to weigh in. In addition, the rebound in the biotech sector is finally taking hold. Couple that to the expected Santa Clause rally and you have a lot of upside potential for NKTR.